Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Recent advances in nanotheranostics for triple negative breast cancer treatment

Fig. 2

Diagrammatic representation of ligands and their specific receptors: Folate receptor is targeted by folic acid-conjugated gold nanorod as nanotherapeutics. Similarly, various other receptors like CD44 and CXCR4 are identified by HA-PTX nanoconjugate and HA-PTX poly(lactide-co-glycolide) nanoparticle respectively increases the specificity and decrease the adverse effects of the cancer therapy.

Back to article page